Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial
Obesity · 2026-03 · 34 (3) · 524-536
DOI: 10.1002/oby.70108 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, online erschienen am 21.01.2026. Verfasst von Alejandro Campos und 15 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Phentermine, Topiramate, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vivus LLC, Vivus.
Abstract (Originalsprache)
Objective
This study compared the effects of phentermine‐topiramate‐ER (mid‐dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI).
Methods
We conducted a 12‐month, randomized, double‐blind, placebo‐controlled trial at a single tertiary academic center in the United States (June 2020–June 2022). Eighty participants with obesity (BMI ≥ 30 kg/m 2 ) were enrolled in the DELI program, consisting of in‐person and telehealth modalities, dietary and physical activity goals, and use of a smartphone application integrated with digital devices (Apple Watch and Bluetooth‐enabled weight scale and blood pressure monitor). Participants were randomized 1:1 to receive either phentermine‐topiramate‐ER ( n = 42) or placebo ( n = 38) in addition to the DELI.
Results
At 3 months, the phentermine‐topiramate group lost a mean of 10.82 kg versus 4.04 kg in the placebo group (mean difference −6.78 kg; p = 0.002). At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference −9.48 kg; p < 0.001). Participants receiving phentermine‐topiramate‐ER experienced a 3.35% reduction in the estimated atherosclerotic CVD risk compared to baseline ( p = 0.004).
Conclusions
Phentermine‐topiramate‐ER, when combined with a DELI, produced significant and sustained weight loss and reduced CVD risk in adults with obesity. Trial Registration ClinicalTrials.gov : NCT04408586
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Biomedical Statistics & Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
- Vivus LLC, Campbell, California, USA.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Alejandro Campos, Wissam Ghusn, Diego Anazco, Heather J Gunn, Maria D Hurtado, Andres Acosta
Förderung
- Vivus LLC
- Vivus
Zitieren
APA
Campos, A., Ghusn, W., Cifuentes, L., Sacoto, D., Fansa, S., Anazco, D., Ricardo-Silgado, M. L., Hashem, A., Schaefer, M., Harmsen, W. S., Gunn, H. J., Peterson, C., Larsen, D., Varghese, S. T., Hurtado, M. D., & Acosta, A. (2026). Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial. Obesity, 34(3), 524-536. https://doi.org/10.1002/oby.70108
Vancouver
Campos A, Ghusn W, Cifuentes L, Sacoto D, Fansa S, Anazco D, et al. Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial. Obesity. 2026;34(3):524-536. doi:10.1002/oby.70108
BibTeX
@article{Campos2026,
author = {Campos, Alejandro and Ghusn, Wissam and Cifuentes, Lizeth and Sacoto, Daniel and Fansa, Sima and Anazco, Diego and Ricardo-Silgado, Maria L and Hashem, Anas and Schaefer, Megan and Harmsen, William S and Gunn, Heather J and Peterson, Craig and Larsen, Deborah and Varghese, Santosh T and Hurtado, Maria D and Acosta, Andres},
title = {Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial},
journal = {Obesity},
year = {2026},
volume = {34},
number = {3},
pages = {524--536},
doi = {10.1002/oby.70108}
}
EUVIMED